Dergiler / Türk Göğüs Kalp Damar Cerrahisi Dergisi / 2012 / Cilt: 20 - Sayı: 3

The outcomes of transcatheter aortic valve implantation with Edwards SAPIEN or CoreValve devices: Single-center experience in Turkey

Edwards SAPIEN ve CoreValve cihazlar ile transkateter aort kapak implantasyonu sonuçları: Türkiye’den tek merkezli deneyim

Sayfa
434–441
DOI
—

Özet

Amaç: Bu çalışmada transkateter aort kapak implantasyonunun erken ve orta dönem sonuçları değerlendirildi. Çalışma planı: Ekim 2010 - Şubat 2012 tarihleri arasında kliniğimizde transkateter aort kapak implantasyonu yapılan, cerrahi riski yüksek (EuroSCORE 26.0±9.9) 35 hasta (16 erkek, 19 kadın; ort. yaş 77.4±6.9 yıl; dağılım 58-91 yıl) çalışmaya dahil edildi. Edwards SAPIEN (n=27) ve CoreValve protezler (n=8) transfemoral (n=33), transapikal (n=1), subklavian (n=1) yaklaşım ile yerleştirildi. Hastaların işlem öncesi ekokardiyografik ortalama kapak alanı 0.6±0.1 cm2, ortalama transvalvüler gradiyent 53.3±8.0 mmHg idi. Bulgular: İşlemin başarı oranı %97 idi. İşlem sonrasında ortalama transvalvüler gradiyent 9.8±2.7 mmHg’ye gerilerken (p

Abstract

Background: This study aims to evaluate early- and midterm outcomes of transcatheter aortic valve implantation. Methods: Between October 2010 and February 2012, 35 patients (16 males, 19 females; mean age 77.4±6.9 years; range 58 to 91 years) who were at high risk for surgery (EuroSCORE 26.0±9.9) and underwent transcatheter aortic valve implantation in our clinic were included. Edwards SAPIEN (n=27) and CoreValve prostheses (n=8) were implanted by transfemoral (n=33), transapical (n=1), and subclavian (n=1) approaches. The mean preoperative echocardiographic valve area was 0.6±0.1 cm2, while the mean transvalvular gradient was 53.3±8.0 mmHg. Results: The procedural success rate was 97%. Following the procedure, the mean transvalvular gradient decreased to 9.8±2.7 mmHg, whereas the average aortic valve area increased to 1.9±0.2 cm2. The mean NYHA functional capacity reduced from 3.5±0.5 before the procedure to 1.4±0.6 at three months during follow-up (p